Practitioner’s Guide to Â鶹Éç

Jump to:
Medical advisors icon

Meet our

Medical advisors

Daniel Guillen, MD

Daniel Guillen, MD

Jonathan Soslow, MD, MSCI

Jonathan H. Soslow, MD, MSCI

Future Directions in Duchenne Muscular Dystrophy Treatment

Written by Margaret Anne Rockwood | Last updated June 3rd, 2026
✅ Medically reviewed by Jonathan Soslow, MD

Ìý

TheÌýU.S. Food and Drug AdministrationÌýhas adopted a relatively flexible and facilitative approach to therapies forÌýDuchenne muscular dystrophy (Â鶹Éç), reflecting its status as a rare, progressive, and life-limiting disorder with significant unmet medical need.

Many Â鶹Éç therapies qualify forÌýorphan drug designation, which provides incentives that include market exclusivity, tax credits, and expedited development pathways.

In addition, several agents have been authorized under the FDA’sÌýaccelerated approvalÌýframework, based on surrogate endpoints like dystrophin expression, relying on post-marketing studies to confirm clinical benefit.

Expanded access (compassionate use) programs have also been employed to enable select patients with limited treatment options to receive investigational therapies outside of clinical trials.

Pharmacologic Therapies

Nonsense Mutation Readthrough Therapies

Nonsense mutation readthrough therapies —Ataluren (Translarna), Gentamicin (aminoglycoside antibiotic) —and several other compounds are designed for the subset of patients with premature stop codons in the dystrophin gene. These drugs promote ribosomal readthrough of premature termination signals during translation. They do not correct the underlying mutation or restore the reading frame; instead, they allow the ribosome toÌýignore that premature stop codon, enabling production of a truncated but partially functional dystrophin protein.

Though clinical benefit has been variable, this approach remains an important mutation-specific strategy and continues to be refined in ongoing studies. Though approved in some countries, it is not yet FDA-approved in the U.S.

Anti-Fibrotic Therapies

A growing area of interest involves therapies that target downstream pathophysiologic processes in Â鶹Éç, including chronic inflammation, fibrosis, and muscle degeneration. New agents target pathways such as TGF-β and NF-κB to help preserve muscle integrity and slow functional decline. These therapies do not directly restore dystrophin, but may enhance the effectiveness of gene- and cell-based approaches by improving the muscle environment.

New Therapies for Protecting the Heart

DHF for Longer Maintenance of Cardiac Function

Ifetroban, an oral drug that blocks thromboxane receptor signaling is a promising, though preliminary, new therapy to protect heart function. Its mechanism reduces inflammation, fibrosis, and vascular dysfunction—key contributors to cardiac decline in Â鶹Éç.

In a Phase 2 clinical trial (FIGHT Â鶹Éç) ifetroban showed encouraging signals of improved cardiac function, including left ventricular ejection fraction. These findings highlight a shift toward therapies that directly target cardiac pathology rather than treating it as a secondary complication.

AAV Therapies

Adeno-associated viral (AAV) gene therapy has become one of the most important emerging treatments for Â鶹Éç because it targets the underlying absence of dystrophin rather than only managing downstream complications.

Elevidys, FDA-approved in 2023,Ìýis the first FDA-approved gene therapy for Â鶹Éç. It uses an AAV vector to deliver a shortened microdystrophin gene that enables muscle cells to produce a dystrophin-like protein.

Restricted gene size, immune responses to the viral vector, inability to re-dose after treatment, and uncertainty regarding long-term durability and clinical benefit are current challenges. Safety concerns have also emerged, including cases of serious acute liver injury that prompted the FDA to issue safety communications, update monitoring recommendations, and revise prescribing information.

Next-Generation Gene Therapy Approaches

Next-generation AAV-based therapies for Â鶹Éç are focused on improved vector engineering to enhance delivery to skeletal and cardiac muscle and enable more effective dystrophin restoration. Because the full dystrophin gene exceeds the packaging capacity of conventional AAV vectors, dual-vector and other expanded-capacity systems are being developed to deliver larger and potentially more functional dystrophin constructs. Researchers are also investigating less immunogenic and potentially re-dosable AAV platforms to overcome immune limitations and improve long-term therapeutic durability.

Although most of these approaches remain in preclinical or early translational development, they represent a new frontier in future Â鶹Éç therapy.

Exon-Skipping Therapies

Exon-skipping therapies are already established treatments for specific genetic subtypes of Â鶹Éç and include approved agents such as eteplirsen, golodirsen, viltolarsen, and casimersen.

These antisense oligonucleotide (ASO) therapies work by modifying pre-mRNA splicing to skip targeted exons, restoring the reading frame and allowing production of a shorter, but partially functional, dystrophin protein.

Ongoing research is focused on next-generation ASOs and multi-exon skipping strategies that could improve dystrophin restoration and make exon-skipping applicable to a much larger proportion of Â鶹Éç patients.

CRISPR-Based Gene Editing

Gene editing approaches, particularly CRISPR/Cas9-based technologies, are being developed to enable permanent correction of mutations inÌýÂ鶹Éç. These strategies aim to restore dystrophin expression within the genome from an out-of-frame format to an in-frame format. This would allow for production of a more physiologic, potentially near full-length, dystrophin protein.

Preclinical CRISPR/Cas9 studies have demonstrated successful dystrophin restoration in animal models, and aÌýfirst-in-human in vivo gene editing therapy trial (PBGENE-Â鶹Éç)Ìýhas received FDA clearance to begin aÌýPhase 1/2 trial.

Clinical trials of a small molecule utrophin upregulator, Ezutromid (SMT C1100), were discontinued, but researchers are investigating a CRISPR approach to upregulation.

Key challenges in CRISPR-based therapies include means of efficient and widespread delivery to skeletal and cardiac muscle, mitigation of off-target effects, and management of immune responses to both the vector and gene-editing components. Despite these hurdles, gene editing represents a potentially transformative, one-time therapeutic approach.

Cell-Based Therapies Under Investigation

Preclinical studies demonstrate that mesenchymal stem/progenitor cells (MSCs) can contribute to muscle fiber regeneration and potentially restore dystrophin expression, through immunomodulatory and anti-inflammatory effects that improve the dystrophic milieu.

Emerging platforms using induced pluripotent stem cell (iPSC)-derived muscle progenitors offer the theoretical advantage of autologous transplantation with ex vivo gene correction prior to engraftment. While the limited number of completed early-phase clinical studies and case series suggest that cell-based therapies are generally feasible and appear safe, efficacy signals remain modest and barriers significant.

Cardiosphere-derived cells (CDCs) have been evaluated in Â鶹Éç due to their anti-inflammatory and anti-fibrotic properties. Unlike stem cells, CDCs do not require cell engraftment but exert their anti-inflammatory and anti-fibrotic properties through the release of exosomes. A phase III study was recently completed evaluating deramiocel for both skeletal muscle and cardiac benefits. The study demonstrated improvement of the primary and all type-1 error controlled secondary outcomes, and FDA approval is expected in 2026. If approved with a cardiac indication, deramiocel would be the first FDA-approved therapeutic for Â鶹Éç cardiomyopathy.

Additional Therapies

Additional investigational therapies are also being explored beyond traditional pathways.ÌýSevasemtenÌýis a skeletal muscle myosin inhibitor designed to improve muscle function and reduce contraction-related injury.ÌýSardocorÌýis evaluating an investigational AAV-based therapy focused on calcium-handling pathways, representing a mechanistically distinct approach to Â鶹Éç gene therapy.

Molecularly Targeted Treatment

Approaches Under Investigation for Â鶹Éç

Scroll horizontally to view all columns -->

Treatment / Strategy Primary Target Stage of Research / Clinical Use
Ataluren (Translarna) Premature stop codons (nonsense mutations) allowing ribosomal readthrough Approved in some countries; not FDA-approved in U.S.; ongoing refinement
Gentamicin (aminoglycoside) Premature stop codon readthrough Experimental / limited investigational use
Other nonsense readthrough compounds Premature stop codons in dystrophin gene Preclinical to early clinical investigation
Anti-fibrotic therapies (TGF-β targeting) Fibrosis pathway / TGF-β signaling Pamrevlumab; Investigational / early-stage development
NF-κB pathway inhibitors Chronic inflammation and degeneration Edasalonexent; Investigational / preclinical to early clinical
Next-generation corticosteroid alternatives Inflammation with fewer steroid side effects Vamorolone, a dissociative steroid was FDA-approved in 2023; others under investigation
Next-generation AAV gene therapy Improved dystrophin replacement via better vectors Elevidys, SGT-003, RGX-202 Active development / next-generation refinement
Dual-vector AAV systems Larger gene payload delivery Preclinical to early translational research
Re-dosable / less immunogenic AAV vectors Reduced immune response and repeat dosing Preclinical / translational development
CRISPR/Cas9 gene editing Permanent correction of dystrophin gene mutations Preclinical; first-in-human Phase 1/2 (PBGENE-Â鶹Éç) beginning
Ifetroban Thromboxane receptor signaling → cardiac inflammation/fibrosis Phase 2 clinical trial (FIGHT Â鶹Éç)
Mesenchymal stem/progenitor cells (MSCs) Muscle regeneration + immunomodulation Early clinical / preclinical
iPSC-derived muscle progenitors Regeneration + potential autologous corrected cell therapy Preclinical / early translational
Cardiosphere-derived cells Cardiac and skeletal muscle support CAP-1002 (deramiocel) under FDA review
Other progenitor cell therapies Muscle repair and regeneration Early clinical / experimental
Utrophin upregulation Increase utrophin to compensate for dystrophin absence Preclinical and early development stages
Combination gene + cell therapy approaches Gene correction + regeneration together Future strategy / conceptual + early preclinical

Future Strategies

Future strategies may involve combination therapies such as:

  • dystrophin restoration + anti-fibrotic therapy
  • gene therapy + cardioprotection
  • exon skipping + HDAC modulation

These approaches integrate gene correction with cell-based regeneration to address both the primary genetic defect and the progressive loss of muscle tissue.

References

  1. Birnkrant D. J., et al. (2018). Lancet Neurology.
  2. Birnkrant D. J., et al. (2018). Lancet Neurology.
  3. Birnkrant D. J., et al. (2018). Lancet Neurology.
  4. ClinicalTrials.gov
  5. McDonald C. M., et al. (2018). The Lancet.
  6. Quattrocelli M., et al. (2021). Journal of Neuromuscular Diseases.
  7. Ward L. M., et al. (2018).
  8. Mercuri E., et al. (2024). Lancet Neurology.
  9. LoMauro A., Aliverti A. (2015/updated clinical use reflected in 2016 care guidelines). Therapeutics and Clinical Risk Management.
  10. McNally E. M., et al. (2015; still foundational and incorporated into 2018+ care guidelines).
  11. Raman S. V., et al. (2015; still standard evidence base in modern care guidelines). Lancet Neurology.
  12. Buddhe S., et al. (2018).
  13. Charleston J. S., et al. (2018). Annals of Neurology.
  14. Frank D. E., et al. (2020).
  15. Komaki H., et al. (2020). Annals of Clinical and Translational Neurology.
  16. Wagner K. R., et al. (2021). Muscle & Nerve.
  17. U.S. Food and Drug Administration. (2024).
  18. U.S. Food and Drug Administration. (2025).
  19. Elevidys.

Ìý